Interferon-β-1a (Avonex) 30 mcg and 60 mcg are equally effective in patients with relapsing multiple sclerosis:: results from the Cyprus study site of the European IFNβ-1a Dose Comparison Study

被引：0
|
作者：
Kkolou, E [1 ]
Papacostas, S [1 ]
Kyriallis, K [1 ]
Toufexis, J [1 ]
Pantzaris, M [1 ]
机构：
[1] Cyprus Inst Neurol & Genet, Nicosia, Cyprus
来源：
MULTIPLE SCLEROSIS | 2004年 / 10卷 / 7032期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S243 / S243
页数：1
相关论文
共 50 条
  • [1] Interferon β-1a in relapsing multiple sclerosis:: four-year extension of the European IFNβ-1a Dose-Comparison Study
    Clanet, M
    Kappos, L
    Hartung, HP
    Hohlfeld, R
    MULTIPLE SCLEROSIS, 2004, 10 (02): : 139 - 144
  • [2] Neuropsychological effects of Avonex® (interferon-β-1a) in relapsing multiple sclerosis (MS)
    Fischer, JS
    Priore, R
    Jacobs, L
    Cookfair, D
    Rudick, R
    Herndon, R
    Richert, J
    Salazar, A
    Goodkin, D
    Granger, C
    Simon, J
    Grafman, J
    Lezak, M
    O'Reilly, K
    Schacter, M
    Shucard, D
    Davidson, A
    Wende, K
    NEUROLOGY, 1998, 50 (04) : A32 - A33
  • [3] Effect of neutralising antibody (NAb) development on efficacy of interferon (IFN) β-1A (Rebif®), 44 MCG subcutaneously three times weekly, compared with IFN β-1A (Avonex®), 30 MCG intramuscularly once weekly:: Results from the evidence study
    Sharief, MK
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2003, 74 (10): : 1450 - 1450
  • [4] A pilot study of the effect of weekly intramuscular 30 mcg interferon β-1a (Avonex™) on monthly gadolinium-enhanced brain MRI activity in patients with relapsing multiple sclerosis.
    Waubant, E
    Sloan, R
    Andersson, PB
    Goodkin, D
    REVUE NEUROLOGIQUE, 1999, 155 : S20 - S23
  • [5] A study of the effect of gender on interferon beta-1a (Avonex® 30 mcg) treatment in patients with multiple sclerosis
    Munschauer, FE
    Herndon, R
    Sandrock, AW
    Tsao, E
    Berkhoff, JE
    Stubbendick, A
    MULTIPLE SCLEROSIS, 2005, 11 : S78 - S78
  • [6] Comparison of interferon-β-1a 22 mcg once a week and interferon-β-1b 250 mcg every other day in a randomised head-to-head study
    Koch-Henriksen, N
    Sorensen, P
    Christensen, T
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S240 - S241
  • [7] Ongoing efficacy and safety analysis of interferon-β1a (AVONEX) in patients with multiple sclerosis
    Herndon, RM
    Coats, M
    Goodkin, D
    Mass, M
    Richert, J
    Rudick, RA
    Weinstock-Guttman, B
    Simonian, NA
    Campion, M
    Scaramocci, J
    Alam, JJ
    Jacobs, LD
    ANNALS OF NEUROLOGY, 1997, 42 (06) : 987 - 987
  • [8] Should patients with relapsing multiple sclerosis be given a higher dose and frequency of interferon-β1a?
    Fox, RJ
    Rudick, RA
    NATURE CLINICAL PRACTICE NEUROLOGY, 2005, 1 (01): : 16 - 17
  • [9] Should patients with relapsing multiple sclerosis be given a higher dose and frequency of interferon-β1a?
    Robert J Fox
    Richard A Rudick
    Nature Clinical Practice Neurology, 2005, 1 : 16 - 17
  • [10] AUtoimmunity PRofile in INterferon β-1a treated multiple sclerosis patients.: The AUPRIN study:: comparison of 2 different dosage of subcutaneous interferon-β-1a
    Verdun, E
    Ricci, A
    Cucci, MA
    Barbero, P
    Pipieri, A
    Clerico, M
    Giordano, L
    Delfico, L
    Tassinari, T
    Motti, L
    Paciello, M
    Reggio, A
    Aimo, G
    Durelli, L
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S251 - S251
12345